Government agencies investing funds in academic research institutes focusing on the research and development for treatment of chemotherapy-induced peripheral neuropathy is driving growth, according to a Report by Research & Markets.
For instance, in November 2018, the U.S. National Cancer Institute awarded$ 2.3M to Indiana University School of Medicine, a research institute in the U.S. The investment was made in Indiana University School of Medicine to accelerate the research and development of small, targeted molecule called APX3330 to prevent or reverse chemotherapy induced peripheral neuropathy (CIPN) caused by cancer drugs.
Peripheral neuropathy is a disorder of the peripheral nerves. These nerves send messages between the central nervous system, the brain and the spinal cord, and the rest of the body. Peripheral neuropathy can result from traumatic injuries, infections, metabolic problems, inherited causes, and exposure to toxins. One of the most common causes is diabetes.
Peripheral neuropathy caused by either type 1 diabetes or type 2 diabetes is called diabetic polyneuropathy.